The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

European regulators back western world’s first gene therapy drug

| | July 23, 2012

European regulators have recommended approval of the Western world’s first gene therapy drug — after rejecting it on three previous occasions — in a significant advance for the novel medical technology.

More than 20 years since the first experiments with the ground-breaking method for fixing faulty genes, scientists and drug companies are still struggling to apply gene therapy in practice.

Friday’s decision by the European Medicines Agency (EMA) is a win for the drug’s maker, the small Dutch biotech company uniQure, and a potential lifeline for patients with the ultra rare genetic disorder lipoprotein lipase deficiency (LPLD).

View the original article here: European regulators back first gene therapy drug – Reuters AlertNet

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend